Muraglitazar

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Diabetes, Type 2

Conditions

Diabetes, Type 2

Trial Timeline

Jun 1, 2003 → Apr 1, 2004

NCT ID

NCT00246987

About Muraglitazar

Muraglitazar is a phase 3 stage product being developed by Bristol Myers Squibb for Diabetes, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT00246987. Target conditions include Diabetes, Type 2.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00240370	Phase 3	Completed	Oct 1, 2003	—	Type 2 Diabetes
NCT00162175	Phase 3	Completed	Jul 1, 2003	Nov 1, 2005	Metabolics Diabetes Nos
NCT00162240	Phase 3	Completed	Jun 1, 2003	May 1, 2004	Diabetes Mellitus
NCT00246987	Phase 3	Completed	Jun 1, 2003	Apr 1, 2004	Diabetes, Type 2
NCT00240383	Phase 2/3	Completed	May 1, 2002	Jun 1, 2006	Diabetes Mellitus II
NCT00245388	Phase 2/3	Completed	Apr 1, 2002	Jul 1, 2002	Dyslipidemia

Competing Products

20 competing products in Diabetes, Type 2

See all competitors

Product	Company	Stage	Hype Score
add-on pioglitazone + add-on sulphonylurea	AMD Biotech	Approved	77
MKP10241 + Placebo	Mankind Pharma	Phase 2	52
Daily injection of KBP/placebo for up to 28 days	Eli Lilly	Phase 1	33
LY3209590 + Insulin Degludec	Eli Lilly	Phase 1	33
AC2993	Eli Lilly	Phase 3	77
LY3209590 + Placebo	Eli Lilly	Phase 1	33
Insulin Lispro Protamine Suspension + Insulin Glargine	Eli Lilly	Phase 3	77
LY2963016 + Lantus	Eli Lilly	Phase 1	33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDs	Eli Lilly	Pre-clinical	23
Insulin Lispro Mix25 + Insulin Lispro Mix50	Eli Lilly	Approved	85
Nasal Glucagon + Intramuscular Glucagon	Eli Lilly	Phase 3	77
Retatrutide + Placebo	Eli Lilly	Phase 1	33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High Dose	Precigen	Phase 1/2	36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SC	Eli Lilly	Phase 1	33
Placebo + Linagliptin	Eli Lilly	Phase 3	77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)	Eli Lilly	Approved	85
teplizumab or placebo	Eli Lilly	Phase 1	33
LY2428757 + Placebo	Eli Lilly	Phase 2	52
Insulin Efsitora Alfa + Insulin Degludec	Eli Lilly	Phase 3	77
LY900014 (SC) + LY900014 (IV)	Eli Lilly	Phase 1	33

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved